Abstract
Background
Protein misfolding within specific brain regions is a common characteristic of neurodegenerative diseases, such as Alzheimer's disease and Parkinson’s disease (PD). Therefore, a common term often used for these disorders is “proteinopathy”. Currently, there has been increasing attention toward the overlap of pathogenesis between proteinopathies.
Aims
We aimed to explore the cross-sectional and longitudinal level of the CSF α-synuclein (α-syn), amyloid βeta (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) in PD subjects with tremor dominant (TD) and a non-tremor dominant (nonTD) subtype from the Parkinson Progression Markers Initiative (PPMI).
Methods
We enrolled 411 early-stage PD patients and 187 healthy controls (HCs) from the PPMI. We compared the level of CSF biomarkers at four time points including baseline, 6 months, 1 year, and 2 years. To investigate longitudinal changes in CSF proteins within each group, we used linear mixed models.
Results
The level of CSF biomarkers was significantly lower in PD patients compared to HCs at any visit. Moreover, there was no statistically significant difference in the level of CSF α-syn, Aβ1-42, t-tau, and p-tau between PD-TD and PD-nonTD. Longitudinal analysis showed significant CSF α-syn reduction after one year from baseline in PD-TD patients (P = 0.047). Also, there was a significant reduction in the level of CSF Aβ1-42 after two years in PD-nonTD patients but not HCs and PD-TD (P = 0.033).
Conclusion
Our results indicate that different patterns in longitudinal changes of CSF biomarkers could be due to different pathophysiological mechanisms involved in each PD motor subtype.
Similar content being viewed by others
Data availability
The datasets analyzed during the current study are available upon request with no restriction.
References
de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535. https://doi.org/10.1016/S1474-4422(06)70471-9
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7
Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G (2005) Burden of illness in Parkinson’s disease. Mov Disord 20(11):1449–1454. https://doi.org/10.1002/mds.20609
Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(S1):318–324. https://doi.org/10.1111/jnc.13691
Kouli A, Torsney KM, Kuan WL. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications Copyright: The Authors.; 2018.
Dickson DW (2012) Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a009258
Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M (1997) α-Synuclein in Lewy bodies. Nature 388(6645):839–840. https://doi.org/10.1038/42166
Burré J, Vivona S, Diao J, Sharma M, Brunger AT, Südhof TC (2013) Properties of native brain α-synuclein. Nature. https://doi.org/10.1038/nature12125
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164. https://doi.org/10.1038/ncb748
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al (2011) In vivo demonstration that & #x3b1;-synuclein oligomers are toxic. Proc Natl Acad Sci 108(10):4194–4199. https://doi.org/10.1073/pnas.1100976108
Jellinger KA (2012) Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 16(6):1166–1183. https://doi.org/10.1111/j.1582-4934.2011.01507.x
Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL et al (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. Faseb j 20(13):2302–2312. https://doi.org/10.1096/fj.06-6092com
Irwin DJ, Lee VMY, Trojanowski JQ (2013) Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 14(9):626–636. https://doi.org/10.1038/nrn3549
Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol 225(1):210–218. https://doi.org/10.1016/j.expneurol.2010.06.017
Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J et al (2007) Tau and alpha-synuclein in susceptibility to, and dementia in Parkinson’s disease. Ann Neurol 62(2):145–153. https://doi.org/10.1002/ana.21192
Marras C, Lang A (2008) Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 70(21):1996–2003. https://doi.org/10.1212/01.wnl.0000312515.52545.51
Marras C, Lang A (2013) Parkinson’s disease subtypes: lost in translation? Journal of Neurology. Neurosurg Psychiat 84(4):409. https://doi.org/10.1136/jnnp-2012-303455
Aleksovski D, Miljkovic D, Bravi D, Antonini A (2018) Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39(11):1971–1976. https://doi.org/10.1007/s10072-018-3522-z
Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al (2013) Association of cerebrospinal fluid β-amyloid 1–42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287. https://doi.org/10.1001/jamaneurol.2013.3861
Elizabeth Qian YH (2019) Aging Dis 10(5):1130–1139
Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF et al (2013) Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(5):537–543. https://doi.org/10.1136/jnnp-2012-303808
Jellinger KA (2012) CSF biomarkers in different phenotypes of Parkinson disease. J Neural Transm (Vienna) 119(4):455–456. https://doi.org/10.1007/s00702-011-0736-0
Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM (2014) Gait and balance in Parkinson’s disease subtypes: objective measures and classification considerations. J Neurol. https://doi.org/10.1007/S00415-014-7513-6
Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Movem Disord Off J Movem Disord Soc 28(5):668–670. https://doi.org/10.1002/mds.25383
Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20(9):1133–1142. https://doi.org/10.1002/MDS.20513
Nabizadeh F, Sodeifian F, Pirahesh K (2022) Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease. Neurol Sci. https://doi.org/10.1007/s10072-022-06110-y
Nabizadeh F, Pirahesh K, Khalili E (2022) Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease. Neurol Sci 43(7):4193–4201. https://doi.org/10.1007/s10072-022-05952-w
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DAT ATOP cohort. Neurology 40(10):1529
Kang J-H, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study. Acta Neuropathol 131(6):935–949
van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, Calabresi P et al (2013) Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson’s disease. Mov Disord 28(6):747–754
Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A (2014) CSF α-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 20(4):382–387
Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F et al (2013) Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8(1):e53250
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T et al (2011) The Parkinson progression marker initiative (PPMI). Prog Neurobiol 95(4):629–635
Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O et al (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9(3):131–140
Park MJ, Cheon S-M, Bae H-R, Kim S-H, Kim JW (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol 7(4):215–222
Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26(3):213–216
Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B et al (2014) Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966–975
Dolatshahi M, Pourmirbabaei S, Kamalian A, Ashraf-Ganjouei A, Yaseri M, Aarabi MH (2018) Longitudinal alterations of alpha-synuclein, amyloid beta, total, and phosphorylated tau in cerebrospinal fluid and correlations between their changes in Parkinson’s disease. Front Neurol 9:560
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ et al (2017) Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 89(19):1959–1969
Abbasi N, Mohajer B, Abbasi S, Hasanabadi P, Abdolalizadeh A, Rajimehr R (2018) Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson’s disease. Mov Disord 33(3):431–439
Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M et al (2017) Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 32(10):1389–1400
Schirinzi T, Sancesario GM, Di Lazzaro G, Biticchi B, Colona VL, Mercuri NB et al (2019) CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinsonism Relat Disord 61:203–206
Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T (2015) Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease. Parkinsonism Relat Disord 21(7):758–764
Parnetti L, Cicognola C, Eusebi P, Chiasserini D (2016) Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson’s diagnosis and prognosis. Biomark Med 10(1):35–49
Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N et al (2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 11(1):41–55
Førland MG, Öhrfelt A, Dalen I, Tysnes O-B, Blennow K, Zetterberg H et al (2018) Evolution of cerebrospinal fluid total α-synuclein in Parkinson’s disease. Parkinsonism Relat Disord 49:4–8
Nabizadeh F, Pirahesh K, Valizadeh P (2022). REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study. J Neurol 1–10
Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D’Amore C et al (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiat 64(10):850–855
Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E (2011) The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry 26(1):100–105
Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K et al (2013) Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer’s disease from other dementia disorders. Dement Geriatr Cogn Disord 36(1–2):99–110
Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F et al (2017) Cross-sectional and longitudinal cognitive correlates of FDDNP PET and CSF amyloid-β and Tau in Parkinson’s disease. J Alzheimers Dis 55(3):1261–1272
Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C et al (2010) CSF Aβ42 and tau in Parkinson’s disease with cognitive impairment. Mov Disord 25(15):2682–2685
Jiménez-Jiménez FJ, Alonso-Navarro H, Garcia-Martin E, Agúndez JA (2014) Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci 8:369
Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69(3):570–580
Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, Kuiperij HB et al (2014) CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 20(1):112–115
Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Munoz E et al (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Move Disord Off J Movem Disord Soc 24(15):2203–2210
Acknowledgements
PPMI–a public-private partnership–is funded by the Michael J. Fox Foundation for Parkinson’s Research funding partners 4D Pharma, Abbvie, Acurex Therapeutics, Allergan, Amathus Therapeutics, ASAP, Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol-Myers Squibb, Calico, Celgene, Dacapo Brain Science, Denali, The Edmond J. Safra Foundation, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics.
Funding
We do not have any financial support for this study.
Author information
Authors and Affiliations
Contributions
FN and FS: designed the study, analyzed the data, and wrote the paper; FN, FS and AK: collected data, analyzed and interpreted the data, and wrote the draft version of the manuscript. The manuscript was revised and approved by all authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest regarding the publication of this paper.
Ethical approval
Since the data in this paper were obtained from the PPMI database (ppmi.loni.usc.edu), it does not include any research involving human or animal subjects.
Consent for publication
This manuscript has been approved for publication by all authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nabizadeh, F., Sodeifian, F. & Kargar, A. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson’s disease. Acta Neurol Belg 123, 1429–1437 (2023). https://doi.org/10.1007/s13760-023-02251-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-023-02251-9